This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ibrahim, A. S. Articles by Edwards, J. E. Search for Related Content PubMed PubMed Citation Articles by Ibrahim, A. S. Articles by Edwards, J. E., Jr.

 Previous Article  |  Next Article 

Infection and Immunity, February 2005, p. 999-1005, Vol. 73, No. 2
0019-9567/05/$08.00+0     doi:10.1128/IAI.73.2.999-1005.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Vaccination with Recombinant N-Terminal Domain of Als1p Improves Survival during Murine Disseminated Candidiasis by Enhancing Cell-Mediated, Not Humoral, Immunity

Department of Medicine, Los Angeles Biomedical Institute at Harbor-UCLA Medical Center, Torrance,¹ David Geffen School of Medicine at UCLA, Los Angeles, California²

Received 26 August 2004/ Returned for modification 27 September 2004/ Accepted 12 October 2004

Candida spp. are opportunistic fungal pathogens that are among the most common causes of nosocomial bloodstream infections. The mortality attributable to disseminated candidiasis is 40 to 50% despite antifungal therapy. Clearly, new strategies are needed to prevent this life-threatening infection. Because risk factors for disseminated candidiasis are well defined and frequently of limited duration, vaccination is an appealing prophylactic strategy. We have identified a cell surface protein, Als1p, that mediates adherence of Candida albicans to a variety of human substrates and plastic. Here we report that immunizing BALB/c mice with the recombinant N-terminal domain of Als1p (rAls1p-N) improved survival during a subsequent challenge with a lethal inoculum of C. albicans. The protective 20-µg dose of rAls1p-N significantly increased Candida stimulation of Th1 splenocytes and increased in vivo delayed-type hypersensitivity. In contrast, antibody titers did not correlate with protection. Finally, the vaccine was not protective in T-cell-deficient mice but was protective in B-cell-deficient mice. These data indicate that the mechanism of action of the rAls1p-N vaccine is stimulation of cell-mediated, rather than humoral, immunity against C. albicans. The majority of efforts to date have focused on the development of passive immunization strategies to prevent or treat disseminated candidiasis. In contrast, our results provide proof of principle for vaccination with an adhesin of C. albicans and emphasize the potential for cell-mediated immune modulation as a prophylactic or therapeutic strategy against disseminated candidiasis.

Editor: T. R. Kozel

This article has been cited by other articles:

• Lin, L., Ibrahim, A. S., Avanesian, V., Edwards, J. E. Jr., Fu, Y., Baquir, B., Taub, R., Spellberg, B. (2008). Considerable Differences in Vaccine Immunogenicities and Efficacies Related to the Diluent Used for Aluminum Hydroxide Adjuvant. CVI 15: 582-584 [Abstract] [Full Text]  
• Richard, M. L., Plaine, A. (2007). Comprehensive Analysis of Glycosylphosphatidylinositol-Anchored Proteins in Candida albicans. Eukaryot Cell 6: 119-133 [Full Text]  
• Ibrahim, A. S., Spellberg, B. J., Avanesian, V., Fu, Y., Edwards, J. E. Jr. (2006). The Anti-Candida Vaccine Based on the Recombinant N-Terminal Domain of Als1p Is Broadly Active against Disseminated Candidiasis.. Infect. Immun. 74: 3039-3041 [Abstract] [Full Text]  
• Orsborn, K. I., Shubitz, L. F., Peng, T., Kellner, E. M., Orbach, M. J., Haynes, P. A., Galgiani, J. N. (2006). Protein Expression Profiling of Coccidioides posadasii by Two-Dimensional Differential In-Gel Electrophoresis and Evaluation of a Newly Recognized Peroxisomal Matrix Protein as a Recombinant Vaccine Candidate. Infect. Immun. 74: 1865-1872 [Abstract] [Full Text]  
• Spellberg, B. J., Ibrahim, A. S., Avenissian, V., Filler, S. G., Myers, C. L., Fu, Y., Edwards, J. E. Jr. (2005). The Anti-Candida albicans Vaccine Composed of the Recombinant N Terminus of Als1p Reduces Fungal Burden and Improves Survival in Both Immunocompetent and Immunocompromised Mice. Infect. Immun. 73: 6191-6193 [Abstract] [Full Text]